BPH (Benign Prostatic Hyperplasia)BPHBPH With Other Lower Urinary Tract Symptoms
Investigational drug(s) / intervention(s)
INTUPRO ionic fluid
INTUPRO ionic fluid: Under TRUS imaging, a fixed dose of the ablative agent will be administered to patients by the physician via needle. Each patient will receive a total of 4-10 mL ionic fluid , administered as two separate 2-5 mL injections into each side of the prostatic urethra.
Study summary
The goal of this clinical trial is to determine whether INTUPRO can improve the quality of life in patients with Benign Prostate Hyperplasia (BPH).
The main questions it aims to answer are:
Can INTUPRO treatment lead to the removal of the Foley catheter? Can INTUPRO treatment improve urinary flow? Can INTUPRO treatment lower or minimize waking during sleep to urinate? Can INTUPRO reduce urinary hesitancy, urgency and frequency?
Participants will:
Receive INTUPRO treatment on Day 1. Visit at Day 30 and Day 90 for checkups, tests and Prostate MRI.
Eligibility
Sex
MALE
Min age
45 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* • Male patient aged 45 years or older
* Prostate volume greater than 30 grams
* An International Prostate Symptom Score (IPSS) of 12 or higher
* Presence of obstructive urinary symptoms, such as difficulty starting urination, leakage of urine after voiding, or a feeling of incomplete bladder emptying.
This criterion may include patients who have previously been diagnosed with prostate cancer and completed treatment, but are experiencing urinary problems.
* Life expectancy of at least 3 months
* Ability to understand the study information and provide written informed consent
* Willingness and ability to comply with all study requirements, including procedures, clinical assessments, and follow-up visits
Exclusion Criteria:
* Urethral stricture
* Bladder stones
* Prostate volume 120 grams or greater
* Presence of a prostate median lobe
* History of bladder cancer or kidney cancer, and/or prior surgery related to these conditions
* Previous radiation therapy to the pelvic region
* Prior invasive surgical treatment for BPH symptoms
* The Principal Investigator believes the patient would not tolerate the procedure
* Presence of a cognitive impairment that, in the opinion of the Principal Investigator, would interfere with the patient's ability to provide reliable data or to safely complete the study
* Bleeding disorders
* Known allergy or intolerance to MRI contrast agents required for imaging used to evaluate treatment effectiveness after ionic fluid application
* Other significant concurrent medical conditions that, in the investigator's judgment, could prevent clinical benefit from the procedure or could place the patient or study objectives at risk (including, but not limited to, active infection, kidney dysfunction, or significant comorbidities)
* Significant medical or psychiatric illness
* Participation in another clinical study involving a device, drug, or procedure that has not been completed or that could affect the outcomes of this study
* Inability or unwillingness to undergo MRI examinations during the study period for any reason
Primary outcome measure(s)
Change in Urinary Symptoms (IPSS Score) — 3 months The change in the International Prostate Symptom Score (IPSS) from baseline will be evaluated after treatment. IPSS scores recorded at the screening visit will be compared with scores obtained at the 1-month and 3-month follow-up visits. A reduction in the IPSS score at 1 month and 3 months compared with baseline will be considered a primary outcome measure.
Procedure-Related and Post-Procedure Complications — 3 months Complications related to the procedure and the postoperative period will be assessed at 1 day, 1 month, and 3 months after treatment. The following complications will be specifically monitored:
* Urinary retention
* Urinary tract infection, suggested by a positive urine culture
* Urosepsis
* Blood in the urine (hematuria)
* Perineal hematoma
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.